A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer’s disease
Year: 2016
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Alzheimer s Disease
DOI: 10.3233/jad-160369
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: bapineuzumab, Alzheimer's disease
Open Access status: closed
OpenAlex ID: W2508694778
